牛磺罗定对临床分离株的活性：与导管相关血流感染的相关性。
activity of taurolidine against clinical isolates: relevance to catheter-related bloodstream infections.
机构信息
Department of Pharmacology, Weill Cornell Medicine, New York, New York, USA.
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
出版信息
Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0038124. doi: 10.1128/aac.00381-24. Epub 2024 Jun 12.
Abstract
is an evolving and concerning global threat. Of particular concern are bloodstream infections related to central venous catheters. We evaluated the activity of taurolidine, a broad-spectrum antimicrobial in catheter lock solutions, against 106 . isolates. Taurolidine was highly active with a MIC/MIC of 512/512 mg/L, over 20-fold lower than lock solution concentrations of ≥13,500 mg/L. Our data demonstrate a theoretical basis for taurolidine-based lock solutions for prevention of catheter-associated infections.
摘要
是一种不断演变且令人担忧的全球威胁。尤其令人关注的是与中心静脉导管相关的血流感染。我们评估了牛磺罗定作为一种广谱抗菌剂在导管封管液中的活性，针对 106 株 分离株。牛磺罗定具有高度活性，MIC/MIC 为 512/512mg/L，比浓度≥13500mg/L的封管液低 20 多倍。我们的数据为基于牛磺罗定的封管液预防导管相关性感染提供了理论基础。
相似文献
1
activity of taurolidine against clinical isolates: relevance to catheter-related bloodstream infections.
Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0038124. doi: 10.1128/aac.00381-24. Epub 2024 Jun 12.
2
Minocycline-EDTA-Ethanol Antimicrobial Catheter Lock Solution Is Highly Effective for Eradication of Candida auris Biofilms.
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02146-19.
3
Comparison of ML8-X10 (a prototype oil-in-water micro-emulsion based on a novel free fatty acid), taurolidine/citrate/heparin and vancomycin/heparin antimicrobial lock solutions in the eradication of biofilm-producing staphylococci from central venous catheters.
J Antimicrob Chemother. 2014 Dec;69(12):3263-7. doi: 10.1093/jac/dku281. Epub 2014 Aug 4.
4
Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT).
Trials. 2018 May 2;19(1):264. doi: 10.1186/s13063-018-2647-y.
5
Taurolidine and Heparin as Catheter Lock Solution for Central Venous Catheters in Hemodialysis.
Am J Ther. 2024;31(4):e398-e409. doi: 10.1097/MJT.0000000000001736. Epub 2024 May 7.
6
Antimicrobial activity of hemodialysis catheter lock solutions in relation to other compounds with antiseptic properties.
PLoS One. 2021 Oct 7;16(10):e0258148. doi: 10.1371/journal.pone.0258148. eCollection 2021.
7
Absence of microbial adaptation to taurolidine in patients on home parenteral nutrition who develop catheter related bloodstream infections and use taurolidine locks.
Clin Nutr. 2013 Aug;32(4):538-42. doi: 10.1016/j.clnu.2012.11.014. Epub 2012 Dec 5.
8
Significant reduction in central venous catheter-related bloodstream infections in children on HPN after starting treatment with taurolidine line lock.
J Pediatr Gastroenterol Nutr. 2012 Oct;55(4):403-7. doi: 10.1097/MPG.0b013e31825bb0ae.
9
Use of 2% taurolidine lock solution for treatment and prevention of catheter-related bloodstream infections in neonates: a feasibility study.
J Hosp Infect. 2024 Jan;143:76-81. doi: 10.1016/j.jhin.2023.11.003. Epub 2023 Nov 14.
10
EDTA and Taurolidine Affect Pseudomonas aeruginosa Virulence -Impairment of Secretory Profile and Biofilm Production onto Peritoneal Dialysis Catheters.
Microbiol Spectr. 2021 Dec 22;9(3):e0104721. doi: 10.1128/Spectrum.01047-21. Epub 2021 Nov 17.
本文引用的文献
1
Candida auris Blood stream infection- a descriptive study from Qatar.
BMC Infect Dis. 2023 Aug 6;23(1):513. doi: 10.1186/s12879-023-08477-5.
2
Candida auris‒Associated Hospitalizations, United States, 2017-2022.
Emerg Infect Dis. 2023 Jul;29(7):1485-1487. doi: 10.3201/eid2907.230540.
3
Worsening Spread of in the United States, 2019 to 2021.
Ann Intern Med. 2023 Apr;176(4):489-495. doi: 10.7326/M22-3469. Epub 2023 Mar 21.
4
Antifungal activity of Taurolidine against Mucorales: An in vitro study on clinical isolates.
Curr Med Mycol. 2022 Mar;8(1):26-31. doi: 10.18502/cmm.8.1.9211.
5
Candida auris Pan-Drug-Resistant to Four Classes of Antifungal Agents.
Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0005322. doi: 10.1128/aac.00053-22. Epub 2022 Jun 30.
6
Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 Update.
Infect Control Hosp Epidemiol. 2022 May;43(5):553-569. doi: 10.1017/ice.2022.87. Epub 2022 Apr 19.
7
Candida auris Candidemia in Critically Ill, Colonized Patients: Cumulative Incidence and Risk Factors.
Infect Dis Ther. 2022 Jun;11(3):1149-1160. doi: 10.1007/s40121-022-00625-9. Epub 2022 Apr 11.
8
A description of the first Candida auris-colonized individuals in New York State, 2016-2017.
Am J Infect Control. 2022 Mar;50(3):358-360. doi: 10.1016/j.ajic.2021.10.037. Epub 2021 Nov 15.
9
The efficacy of taurolidine containing lock solutions for the prevention of central-venous-catheter-related bloodstream infections: a systematic review and meta-analysis.
J Hosp Infect. 2022 May;123:143-155. doi: 10.1016/j.jhin.2021.10.022. Epub 2021 Nov 9.
10
Development of High-Level Echinocandin Resistance in a Patient With Recurrent Candidemia Secondary to Chronic Candiduria.
Open Forum Infect Dis. 2019 Jun 1;6(7):ofz262. doi: 10.1093/ofid/ofz262. eCollection 2019 Jul.
Zotero 插件